The many flavors of hyperhomocyst(e)inemia: Insights from transgenic and inhibitor-based mouse models of disrupted one-carbon metabolism

Antioxidants and Redox Signaling

Volumn 9, Issue 11, 2007, Pages 1911-1921

  Elmore, C Lee ^a   Matthews, Rowena G ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENOSYLHOMOCYSTEINASE; BETAINE HOMOCYSTEINE METHYLTRANSFERASE; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; S ADENOSYLMETHIONINE;

AMINO ACID METABOLISM; CARBON METABOLISM; ENZYME DEFICIENCY; HUMAN; HYPERHOMOCYSTEINEMIA; METABOLITE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; ANIMALS; CYSTATHIONINE BETA-SYNTHASE; DISEASE MODELS, ANIMAL; FERREDOXIN-NADP REDUCTASE; HYPERHOMOCYSTEINEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; S-ADENOSYLHOMOCYSTEINE; S-ADENOSYLMETHIONINE;

EID: 35448992897     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1795     Document Type: Review

References (73)

1. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, and Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354: 1578-1588, 2006.
2. Brouwer IA, van Dusseldorp M, Thomas CM, Duran M, Hautvast JG, Eskes TK, and Steegers-Theunissen RP. Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial. Am J Clin Nutr 69: 99-104, 1999.
3. Caudill MA, Wang JC, Meinyk S, Pogribny IP, Jernigan S, Collins MD, Santos-Guzman J, Swendseid ME, Cogger EA, and James SJ. Intracellular S-adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyl-deficient cystathionine-β-synthase heterozygous mice. J Nutr 131: 2811-2818, 2001.
4. Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Meinyk S, Lussier-Cacan S, Chen MF, Pai A, John SWM, Smith RS, Bottiglieri T, Bagley P, Selhub J, Rudnicki MA, James SJ, and Rozen R. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 10: 433-443, 2001.
5. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, and Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324: 1149-1155, 1991.
6. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, and Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55: 1449-1455, 1998.
7. Collinsova M, Strakova J, Jiracek J, and Garrow TA. Inhibition of betaine-homocysteine S-methyltransferase causes hyperhomocysteinemia in mice. J Nutr 136: 1493-1497, 2006.
8. Daly LE, Kirke PN, Molloy AM, Weir DG, and Scott JM. Folate levels and neural tube defects: implications for prevention. JAMA 274: 1698-1702, 1995.
9. Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR, Sigmund CD, Heistad DD, Faraci FM, and Lentz SR. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Circ Res 88: 1203-1209, 2001.
10. Dayal S, Devlin AM, McCaw RB, Liu ML, Arning E, Bottiglieri T, Shane B, Faraci FM, and Lentz SR. Cerebral vascular dysfunction in methionine synthase-deficient mice. Circulation 112: 737-744, 2005.
11. Dekker GA, de Vries JI, Doelitzsch PM, Huijgens PC, von Blomberg BM, Jakobs C, and van Geijn HP. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 173: 1042-1048, 1995.
12. Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ, and Goodfellow J. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 105: 22-26, 2002.
13. Elmore CL, Wu X, Leclerc D, Watson ED, Bottiglieri T, Krupenko NI, Krupenko SA, Cross JC, Rozen R, Gravel RA, and Matthews RG. Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase. Mol Genet Metab 91: 85-97, 2007.
14. Faraci FM and Lentz SR. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke 35: 345-347, 2004.
15. Fenton WA and Rosenberg LE. Inherited disorders of cobalamin transport and metabolism. In: The metabolic and molecular bases of inherited disease, edited by Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill, 1995, pp. 3129-3150.
16. Finnell RH, Spiegelstein O, Wlodarczyk B, Triplett A, Pogribny IP, Melnyk S, and James JS. DNA methylation in Folbp1 knockout mice supplemented with folic acid during gestation. J Nutr 132: 2457S-2461S, 2002.
17. Fisher MC, Zeisel SH, Mar M-H, and Sadler TW. Perturbations in choline metabolism cause neural tube defects in mouse embryos in vitro. FASEB J 16: 619-621, 2002.
18. Fleming A and Copp AJ. Embryonic folate metabolism and mouse neural tube defects. Science 280: 2107-2109, 1998.
19. Ghandour H, Chen Z, Selhub J, and Rozen R. Mice deficient in methylenetetrahydrofolate reductase exhibit tissue-specific distribution of folates. J Nutr 134: 2975-2978, 2004.
20. Green JM, Ballou DP, and Matthews RG. Examination of the role of methylenetetrahydrofolate reductase in incorporation of methyltetrahydrofolate into cellular metabolism. FASEB J 2: 42-47, 1988.
21. Green JM, MacKenzie RE, and Matthews RG. Substrate flux through methylenetetrahydrofolate dehydrogenase: predicted effects of the concentration of methylenetetrahydrofolate on its partitioning into pathways leading to nucleotide biosynthesis or methionine regeneration. Biochemistry 27: 8014-8022, 1988.
22. Heid MK, Bills ND, Hinrichs SH, and Clifford AJ. Folate deficiency alone does not produce neural tube defects in mice. J Nutr 122: 888-894, 1992.
23. Jacobsen DW. Hyperhomocysteinemia and oxidative stress: time for a reality check? Arterioscler Thromb Vasc Biol 20: 1182-1184, 2000.
24. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, and Rozen R. Relationship between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93: 7-9, 1996.
25. Jencks DA and Matthews RG. Allosteric inhibition of methylenetetrahydrofolate reductase by adenosylmethionine: effects of adenosylmethionine and NADPH on the equilibrium between active and inactive forms of the enzyme and on the kinetics of approach to equilibrium. J Biol Chem 262: 2485-2493, 1987.
26. Kapusta L, Haagmans ML, Steegers EA, Cuypers MH, Blom HJ, and Eskes TK. Congenital heart defects and maternal derangement of homocysteine metabolism. J Pediatr 135: 773-774, 1999.
27. Kerr SJ. Competing methyltransferase systems. J Biol Chem 247: 4248-4252, 1972.
28. Kirke PN, Mills JL, and Scott JM. Homocysteine metabolism in pregnancies complicated by neural tube defects. Nutrition 13: 994-995, 1997.
29. Koury MJ, Horne DW, Brown ZA, Pietenpol JA, Blount BC, Ames BN, Hard R, and Koury ST. Apoptosis of late-stage erythroblasts in megaloblastic anemia: association with DNA damage and macrocyte production. Blood 89: 4617-4623, 1997.
30. Kutzbach C and Stokstad ELR. Mammalian methylenetetrahydrofolate reductase: partial purification, properties, and inhibition by S-adenosylmethionine. Biochim Biophys Acta 250: 459-477, 1971.
31. Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, and Dambrink JH. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350: 2673-2681, 2004.
32. LeClerc D, Wilson A, Dumas R, Gafuik C, Song D, Watkins D, Heng HHQ, Rommens JM, Scherer SW, Rosenblatt DS, and Gravel RA. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci U S A 95: 3059-3064, 1998.
33. Lentz SR, Erger RA, Dayal S, Maeda N, Malinow MR, Heistad DD, and Faraci FM. Folate dependence of hyperhomocysteinemia and vascular dysfunction in cystathionine beta-synthase-deficient mice. Am J Physiol Heart Circ Physiol 279: H970-H975, 2000.
34. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, and Genest J Jr. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354: 1567-1577, 2006.
35. Maddox DM, Manlapat A, Roon P, Prasad P, Ganapathy V, and Smith SB. Reduced-folate carrier (RFC) is expressed in placenta and yolk sac, craniofacial region, eye, limb buds and heart. BMC Dev Biol 3: 6, 2003.
36. McCaddon A, Davies G, Hudson P, Tandy S, and Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 13: 235-239, 1998.
37. McKeever MP, Weir DG, Molloy A, and Scott JM. Betaine-homocysteine methyltransferase: organ distribution in man, pig and rat and subcellular distribution in the rat. Clin Science 81: 551-556, 1991.
38. Medical Research Council Vitamin Study Research Group. Prevention of neural tube defects by periconceptual vitamin supplementation. Lancet 338: 131-137, 1991.
39. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, and Scott JM. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 345: 149-151, 1995.
40. Mudd SH, Levy HL, and Skovby F. Disorders of transsulfuration. In: The metabolic and molecular bases of inherited disease, edited by Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill, 1995, pp. 1279-1327.
41. Olteanu H and Banerjee R. Human methionine synthase reductase, a soluble P-450 reductase-like dual flavoprotein, is sufficient for NADPH-dependent methionine synthase activation. J Biol Chem 276: 35558-35563, 2001.
42. Piedrahita JA, Oetama B, Bennett GD, van Waes J, Kamen BA, Richardson J, Lacey SW, Anderson RGW, and Finnell RH. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nat Genet 23: 228-232, 1999.
43. Potena L, Grigioni F, Magnani G, Ortolani P, Coccolo F, Sassi S, Koessels K, Marrozzini C, Marzocchi A, Carigi S, Musuraca AC, Russo A, Magelli C, and Branzi A. Homocysteine-lowering therapy and early progression of transplant vasculopathy: a prospective, randomized, IVUS-based study. Am J Transplant 5: 2258-2264, 2005.
44. Powers RW, Evans RW, Majors AK, Ojimba JI, Ness RB, Crombleholme WR, and Roberts JM. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 179: 1605-1611, 1998.
45. Raijmakers MT, Roes EM, Zusterzeel PL, Steegers EA, and Peters WH. Thiol status and antioxidant capacity in women with a history of severe pre-eclampsia. Br J Obstet Gynaecol 111: 207-212, 2004.
46. Rajkovic A, Catalano PM, and Malinow MR. Elevated homocyst(e)ine levels with preeclampsia. Obstet Gynecol 90: 168-171, 1997.
47. Riddell LJ, Chisholm A, Williams S, and Mann JI. Dietary strategies for lowering homocysteine concentrations. Am J Clin Nutr 71: 1448-1454, 2000.
48. Righetti M, Serbelloni P, Milani S, and Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 24: 379-386, 2006.
49. Robert K, Vialard F, Thiery E, Toyama K, Sinet P-M, Janel N, and London J. Expression of the cystathionine-β-synthase (CBS) gene during mouse development and immunolocalization in adult brain. J Histochem Cytochem 51: 363-371, 2003.
50. Rosenblatt DS. Inherited disorders of folate transport and metabolism. In: The metabolic and molecular bases of inherited disease, edited by Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill, 1995, pp. 3111-3128.
51. Rosenquist TH, Ratashak SA, and Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci U S A 93: 15227-15232, 1996.
52. Rothenberg SP, da Costa MP, Sequeira JM, Cracco J, Roberts JL, Weedon J, and Quadros EV. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 350: 134-142, 2004.
53. Schnyder G, Roffi M, Flammer Y, Pin R, and Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. JAMA 288: 973-979, 2002.
54. Schwahn BC, Laryea MD, Chen Z, Melnyk S, Pogribny I, Garrow T, James SJ, and Rozen R. Betaine rescue of an animal model with methylenetetrahydrofolate reductase deficiency. Biochem J 382: 831-840, 2004.
55. Schwahn BC, Wendel U, Lussier-Cacan S, Mar MH, Zeisel SH, Leclerc D, Castro C, Garrow TA, and Rozen R. Effects of betaine in a murine model of mild cystathionine-beta-synthase deficiency. Metabolism 53: 594-599, 2004.
56. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, and Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346: 476-483, 2002.
57. Shaw GM, O'Malley CD, Wasserman CR, Tolarova MM, and Lammer EJ. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. Am J Med Genet 59: 536-545, 1995.
58. Spence JD, Bang H, Chambless LE, and Stampfer MJ. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. Stroke 36: 2404-2409, 2005.
59. Steegers-Theunissen RP, Boers GH, Blom HJ, Nijhuis JG, Thomas CM, Borm GF, and Eskes TK. Neural tube defects and elevated homocysteine levels in amniotic fluid. Am J Obstet Gynecol 172: 1436-1441, 1995.
60. Steegers-Theunissen RP, Boers GH, Trijbels FJ, and Eskes TK. Neural-tube defects and derangement of homocysteine metabolism. N Engl J Med 324: 199-200, 1991.
61. Swanson DA, Liu M-L, Baker PJ, Garrett L, Stitzel M, Wu J, Harris M, Banerjee R, Shane B, and Brody LC. Targeted disruption of the methionine synthase gene in mice. Mol Cell Biol 21: 1058-1065, 2001.
62. Szabo KT. Congenital malformations in laboratory and farm animal. New York: Academic Press, 1989, pp. 95-143.
63. Tang LS and Finnell RH. Neural and orofacial defects in Folbp1 knockout mice. Birth Defects Res (Part A) 67: 209-218, 2003.
64. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, and Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291: 565-575, 2004.
65. Virdis A, Iglarz M, Neves MF, Amiri F, Touyz RM, Rozen R, and Schiffrin EL. Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice. Arterioscler Thromb Vasc Biol 23: 1352-1357, 2003.
66. Vitvitsky V, Dayal S, Stabler S, Zhou Y, Wang H, Lentz SR, and Banerjee R. Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinemia. Am J Physiol Regul Integr Comp Physiol 287: R39-R46, 2004.
67. Ward M, McNulty H, McPartlin J, Strain JJ, Weir DG, and Scott JM. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. Q J Med 90: 519-524, 1997.
68. Watanabe M, Osada J, Aratani Y, Kluckman K, Reddick R, Malinow MR, and Maeda N. Mice deficient in cystathionine-beta-synthase: animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci U S A 92: 1585-1589, 1995.
69. Wenstrom KD, Johanning GL, Johnston KE, and DuBard M. Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations. Am J Obstet Gynecol 184: 806-812, 2001.
70. Wong WY, Eskes TK, Kuijpers-Jagtman AM, Spauwen PH, Steegers EA, Thomas CM, Hamel BC, Blom HJ, and Steegers-Theunissen RP. Nonsyndromic orofacial clefts: association with maternal hyperhomocysteinemia. Teratology 60: 253-257, 1999.
71. Yeo E-J, Briggs WT, and Wagner C. Inhibition of glycine-N-methyltransferase by 5-methyltetrahydrofolate pentaglutamate. J Biol Chem 274: 37559-37564, 1999.
72. Yeo EJ and Wagner C. Tissue distribution of glycine N-methyltransferase, a major folate-binding protein of rat liver. Proc Natl Acad Sci U S A 91: 210-214, 1994.
73. Zhao R, Russell RG, Wang Y, Liu L, Gao F, Kneitz B, Edelmann W, and Goldman ID. Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem 276: 10224-10228, 2001.